References
- Falco V, Burgos J, Almirante B. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018;19(13):1503–9.
- Liapikou A, Cillóniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015;9:4565–72. Aug 18; eCollection 2015.
- Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, et al. Guidelines for the management of adult lower respiratory tract infections: summary. Clin Microbiol Infect. 2011;17(Suppl 6):1–24.
- Liapikou A, Rosales-Mayor E, Torres A. The management of severe community acquired pneumonia in the intensive care unit. Expert Rev Respir Med. 2014;8(3):293–303.
- Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–9.
- American Thoracic Society, Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.
- Rello J, Ulldemolins M, Lisboa T, Koulenti D, Manez R, Martin-Loeches I, De Waele JJ, Putensen C, Guven M, Deja M., et al. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J. 2011;37(6):1332–9.
- El Solh AA. Ceftobiprole: a new broad-spectrum cephalosporin. Expert Opin Pharmacother. 2009;10(10):1675–86.
- Lovering AL, Michael C, Barbour A, Schmidt S, Rand KH, Derendorf H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2009;34(1):1–7.
- Morosini MI, Díez-Aguilar M, Cantón R. Mechanisms of action and antimicrobial activity of ceftobiprole. Rev Esp Quimioter. 2019;32 (Suppl. 3):03–10 9.
- Awad SS, Rodriguez AH, Chuang Y-C, Marjanek Z, Pareigis AJ, Reis G, Scheeren TWL, Sánchez AS, Zhou X, Saulay M, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59(1):51–61.
- Nicholson SC, Welte T, File TM, Strauss RS, Michiels B, Kaul P, Balis D, Arbit D, Amsler K, Noel GJ, Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with communityacquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39(3):240–6.
- Scheeren TWL, Welte T, Saulay M, Engelhardt M, Santerre-Henriksen A, Hamed K. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials. BMC Infect Dis. 2019;19(1):195.
- Lanks CW, Musani AI, Hsia DW. Community-acquired pneumonia and hospital-acquired pneumonia. Med Clin North Am. 2019;103(3):487–501.
- Slaven EM, Santanilla JI, DeBlieux PM. Healthcare-associated pneumonia in the emergency department. Semin Respir Crit Care Med. 2009;30(1):46–51.
- Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, Perrier A. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141.
- Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med. 2002;166(5):717–23.
- Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, Pesci A, Blasi F, Torres A. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax. 2013;68(11):997–9.
- Arancibia F, Bauer TT, Torres A, Sanchez F, Mensa J, Maldonado A, Rodriguez MJ, Ewig S. Community-acquired pneumonia caused by gram-negative bacteria: incidence and risk and prognosis. Chest. 2016;150(2):415–25.
- Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piñer R, Mensa J, Luque N, Ewig S, Menendez R, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis. 2009;48(4):377–85.